Table 3.
Costs, EQ-5D scores, QALYs, and cost-effectiveness results.
| aLiFE (n = 59) | eLiFE (n = 61) | Control (n = 60) | ||||
|---|---|---|---|---|---|---|
| Mean (SE) | 95% CI | Mean (SE) | 95% CI | Mean (SE) | 95% CI | |
| Total costs | 1,616 (330) | 951 to 2,281 | 1,764 (269) | 1,223–2,306 | 1,729 (540) | 643–2,816 |
| Incremental costsa | −116 | −1,340 to 1,108 | −25 | −1,173 to 1,123 | – | |
| Baseline EQ-5D | 0.8717 (0.0189) | 0.8338 to 0.9096 | 0.8850 (0.0123) | 0.8604 to 0.9097 | 0.8973 (0.0192) | 0.8589 to 0.9357 |
| 6-month EQ-5D | 0.8949 (0.0159) | 0.8630 to 0.9268 | 0.8849 (0.0185) | 0.8479 to 0.9219 | 0.9068 (0.0203) | 0.8662 to 0.9474 |
| 12-month EQ-5D | 0.9090 (0.0125) | 0.8839 to 0.9341 | 0.9004 (0.0169) | 0.8665 to 0.9344 | 0.9156 (0.0161) | 0.8834 to 0.9479 |
| Total QALYs | 0.8926 (0.0142) | 0.8641 to 0.9211 | 0.8888 (0.0149) | 0.8589 to 0.9187 | 0.9066 (0.0181) | 0.8703 to 0.9429 |
| Incremental QALYsb | 0.0060 | −0.0119 to 0.0239 | −0.0063 | −0.0254 to 0.0127 | – | |
| ICER (€/QALY) (intervention vs. control) | Index | – | Comparator | |||
| Incremental NHB at | ||||||
| 30,000 €/QALY | 0.0099 | −0.0071 | – | |||
| 40,000 €/QALY | 0.0089 | −0.0069 | – | |||
| probability pf cost-effectiveness at | ||||||
| 30,000 €/QALY | 66.3% | – | – | |||
| 40,000 €/QALY | 68.2% | – | – | |||
a
Costs adjusted for baseline resource use, age and sex, showing differences in costs between the intervention group and control.
b
QALYs adjusted baseline HRQoL, age and sex, showing difference in QALYs between the intervention group and control.